Sumant Kulkarni
Stock Analyst at Canaccord Genuity
(4.35)
# 1,356
Out of 5,162 analysts
442
Total ratings
44.7%
Success rate
7.2%
Average return
Main Sectors:
Stocks Rated by Sumant Kulkarni
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANVS Annovis Bio | Reiterated: Buy | $17 | $0.7484 | +2,171.51% | 13 | Nov 16, 2026 | |
| GHRS GH Research | Reiterated: Buy | $39 | $18.56 | +110.13% | 19 | Nov 16, 2026 | |
| ZVRA Zevra Therapeutics | Reiterated: Buy | $20 | $9.07 | +120.51% | 23 | Nov 16, 2026 | |
| CRVO CervoMed | Reiterated: Buy | $18 | $1.33 | +1,253.38% | 24 | Nov 10, 2026 | |
| DFTX Definium Therapeutics | Reiterated: Buy | $78 | $29.48 | +164.59% | 22 | Nov 10, 2026 | |
| CMPS COMPASS Pathways | Reiterated: Buy | $20 | $8.65 | +131.21% | 29 | Nov 9, 2026 | |
| ACAD Acadia Pharmaceuticals | Reiterated: Buy | $36 → $38 | $17.59 | +116.03% | 57 | Nov 6, 2026 | |
| LBRX LB Pharmaceuticals | Reiterated: Buy | $65 | $40.04 | +62.34% | 3 | Nov 6, 2026 | |
| VYGR Voyager Therapeutics | Reiterated: Buy | $12 | $1.61 | +645.34% | 43 | Nov 6, 2026 | |
| NBIX Neurocrine Biosciences | Reiterated: Buy | $210 → $220 | $156.59 | +40.49% | 43 | Nov 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $28 | $18.32 | +52.84% | 2 | Nov 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $58 | $26.93 | +115.37% | 19 | Nov 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $21 → $32 | $13.65 | +134.43% | 10 | Oct 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $248 → $272 | $247.13 | +10.06% | 85 | Oct 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $35 → $24 | $6.42 | +273.83% | 3 | Jul 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $50 | $3.50 | +1,328.57% | 12 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $120 → $36 | $0.9461 | n/a | 10 | Jun 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $16.36 | n/a | 4 | Apr 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $66 → $53 | $19.88 | n/a | 8 | Nov 9, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $35 → $19 | $21.39 | n/a | 4 | Nov 7, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $109 | $16.04 | n/a | 2 | Jun 14, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $193.70 | $12.30 | n/a | 7 | Dec 18, 2015 |
Annovis Bio
Nov 16, 2026
Reiterated: Buy
Price Target: $17
Current: $0.7484
Upside: +2,171.51%
GH Research
Nov 16, 2026
Reiterated: Buy
Price Target: $39
Current: $18.56
Upside: +110.13%
Zevra Therapeutics
Nov 16, 2026
Reiterated: Buy
Price Target: $20
Current: $9.07
Upside: +120.51%
CervoMed
Nov 10, 2026
Reiterated: Buy
Price Target: $18
Current: $1.33
Upside: +1,253.38%
Definium Therapeutics
Nov 10, 2026
Reiterated: Buy
Price Target: $78
Current: $29.48
Upside: +164.59%
COMPASS Pathways
Nov 9, 2026
Reiterated: Buy
Price Target: $20
Current: $8.65
Upside: +131.21%
Acadia Pharmaceuticals
Nov 6, 2026
Reiterated: Buy
Price Target: $36 → $38
Current: $17.59
Upside: +116.03%
LB Pharmaceuticals
Nov 6, 2026
Reiterated: Buy
Price Target: $65
Current: $40.04
Upside: +62.34%
Voyager Therapeutics
Nov 6, 2026
Reiterated: Buy
Price Target: $12
Current: $1.61
Upside: +645.34%
Neurocrine Biosciences
Nov 3, 2026
Reiterated: Buy
Price Target: $210 → $220
Current: $156.59
Upside: +40.49%
Nov 3, 2026
Reiterated: Buy
Price Target: $28
Current: $18.32
Upside: +52.84%
Nov 2, 2026
Reiterated: Buy
Price Target: $58
Current: $26.93
Upside: +115.37%
Oct 30, 2026
Reiterated: Buy
Price Target: $21 → $32
Current: $13.65
Upside: +134.43%
Oct 29, 2026
Reiterated: Buy
Price Target: $248 → $272
Current: $247.13
Upside: +10.06%
Jul 27, 2026
Reiterated: Buy
Price Target: $35 → $24
Current: $6.42
Upside: +273.83%
May 15, 2026
Reiterated: Buy
Price Target: $50
Current: $3.50
Upside: +1,328.57%
Jun 12, 2024
Downgraded: Hold
Price Target: $120 → $36
Current: $0.9461
Upside: n/a
Apr 9, 2018
Reiterated: Hold
Price Target: n/a
Current: $16.36
Upside: n/a
Nov 9, 2016
Reiterated: Buy
Price Target: $66 → $53
Current: $19.88
Upside: n/a
Nov 7, 2016
Reiterated: Sell
Price Target: $35 → $19
Current: $21.39
Upside: n/a
Jun 14, 2016
Reiterated: Sell
Price Target: $109
Current: $16.04
Upside: n/a
Dec 18, 2015
Reiterated: Buy
Price Target: $193.70
Current: $12.30
Upside: n/a